Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

• DOI: 10.1126/scitranslmed.abb3631
• Publication Date: 2021-07-14T19:16:26Z
• Authors: Ravi B. Patel; Reinier Hernandez; Peter Carlson; Joseph Grudzinski; Amber M. Bates; Justin C. Jagodinsky; Amy Erbe; Ian R. Marsh; Ian Arthur; Eduardo Aluicio-S...; Raghava N. Sriram...; Won Jong Jin; Christopher Massey; Alexander L. Rakh...; David Vail; Johnathan W. Engle; Trang Le; KyungMann Kim; Bryan Bednarz; Paul M. Sondel; Jamey Weichert; Zachary S. Morris
• Keywords: Immune checkpoint; Radionuclide therapy; Targeted Therapy

Low-dose targeted radionuclide therapy combined with immune checkpoint inhibition enhances complete response rates in preclinical tumor models.